Not sure this is correct...but if you look at the second chart
of the 4 intraday views Steve posted, you will notice letters and
numbers in green. I think he is favoring the notion that 4 is
complete and we are on our way up on 5.
We should see some data in a few months from this study. If
successful,
PEGPH20 could be a
lifesaver for those suffering from hard to treat cancers
-- especially Pancreatic cancer. Halozyme owns 100% of this
technology and plans to "go-it-alone" with this treatment.
The company also has 2 near-term catalysts approaching; the first
one expected is an update from its partner Baxter International (
BAX) which plans to
announce an update in an
earnings conference call on October 17th,
concerning Hylenex recombinant launch Details for Germany and
Scandanavia, plus an FDA re-filing of the drug.
The second is a much bigger catalyst when the Committee for
Medicinal Products for Human Use (CHMP)
convenes October 21-24 to decide whether to
recommend MabThera Subcutaneous (MabTheraSC) to the European
Medical Agency (EMA) for approval.
The CHMP is like a European version of an FDA Advisory Committee
Meeting (ADCOMM), in the sense that a recommendation or opinion is
given for approval or rejection.
In June, the CHMP
announced a positive opinion for Herceptin
and the stock rallied nearly $2 in one day. A similar situation
could be setting up for Halozyme with MabTheraSC, and we feel it
has yet to be valued into the stock.
Halozyme is our best small-cap long-term speculative investment
pick, as we feel a stock price over $20 in the next year is likely,
and potentially over $50 in the next three years or so. One biotech
investor I have spoken with has indicated to me that he holds 2M
shares of Halozyme and agrees with our assessment of Halozyme's
future prospects.
The community is delayed by three days for non registered users.
NQ 20F filed. full compliance
Posted by whs956 on 27th of Oct 2014 at 08:40 am
Major short squeeze going on.
Matt. Awesome work.
Posted by whs956 on 20th of Oct 2014 at 10:06 pm
Nobody bats 1000% Ignore the whiners. People are responsible for their own trades.
chart courtesty wayne 0708
HIgh risk/reward
Posted by whs956 on 20th of Oct 2014 at 03:47 pm
HIgh risk/reward
Posted by whs956 on 20th of Oct 2014 at 03:38 pm
Sky News saying the "NO'S" won
Posted by whs956 on 18th of Sep 2014 at 11:52 pm
Looks like independence lost. Futures ramping up.
Title: SPY dividend this friday.
SDS 120
Posted by whs956 on 15th of Sep 2014 at 03:53 pm
does that effect SDS?
RE: Green View
SPX Intraday Views
Posted by whs956 on 5th of Sep 2014 at 09:11 pm
Not sure this is correct...but if you look at the second chart of the 4 intraday views Steve posted, you will notice letters and numbers in green. I think he is favoring the notion that 4 is complete and we are on our way up on 5.
Central Banks trading futures?
Posted by whs956 on 31st of Aug 2014 at 01:28 am
http://www.zerohedge.com/news/2014-08-30/its-settled-central-banks-trade-sp500-futures
S&P Correction sizes. from zero hedge.
Posted by whs956 on 25th of Aug 2014 at 08:45 pm
4% seems the pattern.
I don't post much
Posted by whs956 on 14th of Aug 2014 at 10:32 am
But read all that you guys share. Thank you for all the hard work!!
yvonne
since 2006
NQ article
Posted by whs956 on 18th of Oct 2013 at 09:06 am
http://seekingalpha.com/article/1753612-nq-mobile-like-a-freight-train-through-the-night-part-1?source=marketwatch
also Macquarie initiates NQ outperform PT 26
$NQ
Posted by whs956 on 17th of Oct 2013 at 11:52 am
$NQ
Posted by whs956 on 17th of Oct 2013 at 11:50 am
Announced special conf call premarket OCT 22nd to announce NEW product
$HALO could just be starting .....
Posted by whs956 on 16th of Oct 2013 at 04:06 pm
SA article:
We should see some data in a few months from this study. If successful, PEGPH20 could be a lifesaver for those suffering from hard to treat cancers -- especially Pancreatic cancer. Halozyme owns 100% of this technology and plans to "go-it-alone" with this treatment.
The company also has 2 near-term catalysts approaching; the first one expected is an update from its partner Baxter International ( BAX) which plans to announce an update in an earnings conference call on October 17th, concerning Hylenex recombinant launch Details for Germany and Scandanavia, plus an FDA re-filing of the drug.
The second is a much bigger catalyst when the Committee for Medicinal Products for Human Use (CHMP) convenes October 21-24 to decide whether to recommend MabThera Subcutaneous (MabTheraSC) to the European Medical Agency (EMA) for approval.
The CHMP is like a European version of an FDA Advisory Committee Meeting (ADCOMM), in the sense that a recommendation or opinion is given for approval or rejection.
In June, the CHMP announced a positive opinion for Herceptin and the stock rallied nearly $2 in one day. A similar situation could be setting up for Halozyme with MabTheraSC, and we feel it has yet to be valued into the stock.
Halozyme is our best small-cap long-term speculative investment pick, as we feel a stock price over $20 in the next year is likely, and potentially over $50 in the next three years or so. One biotech investor I have spoken with has indicated to me that he holds 2M shares of Halozyme and agrees with our assessment of Halozyme's future prospects.
$HALO
Posted by whs956 on 16th of Oct 2013 at 10:20 am
keep an eye on it
30.70 looks to be break point
TWTC
Posted by whs956 on 7th of Oct 2013 at 01:17 pm
ABIO
Posted by whs956 on 7th of Oct 2013 at 01:16 pm
TWTC
Posted by whs956 on 7th of Oct 2013 at 01:14 pm
one more item of interest.... float is 30% short ;)
$NQ fundamental note
Posted by whs956 on 4th of Oct 2013 at 02:15 pm
$NQ fundamental note
Posted by whs956 on 4th of Oct 2013 at 12:53 pm
Piper Jaffray increased price target from $24 to $27
Earnings November 11th. Company announced they will beat estimated earnings for last quarter.